简体
  • 简体中文
  • 繁体中文

热门资讯> 正文

Gilead Sciences将2025财年GAAP每股收益指引从5.85 - 6.15美元上调至6.65 - 6.85美元,而Est为5.98美元

2025-10-31 04:03

GILEAD SCIENCES, INC.
RECONCILIATION OF GAAP TO NON-GAAP 2025 FULL-YEAR GUIDANCE(1)
(unaudited)
                 
(in millions, except percentages and per share amounts)   Provided 

February 11, 2025
  Updated 

April 24, 2025
  Updated 

August 7, 2025
  Updated 

October 30, 2025
Projected product gross margin GAAP to non-GAAP reconciliation:                
GAAP projected product gross margin   77.0% - 78.0%   77.0% - 78.0%   ~ 78.0%   ~ 78.0%
Acquisition-related expenses   ~ 8.0%   ~ 8.0%   ~ 8.0%   ~ 8.0%
Non-GAAP projected product gross margin   85.0% - 86.0%   85.0% - 86.0%   ~ 86.0%   ~ 86.0%
                 
Projected operating income GAAP to non-GAAP reconciliation:                
GAAP projected operating income   $10,200 - $10,700   $10,200 - $10,700   $10,300 - $10,700   $10,300 - $10,600
Acquisition-related, IPR&D impairment and restructuring expenses   ~ 2,500   ~ 2,500   ~ 2,700   ~ 2,800
Non-GAAP projected operating income   $12,700 - $13,200   $12,700 - $13,200   $13,000 - $13,400   $13,100 - $13,400
                 
Projected effective tax rate GAAP to non-GAAP reconciliation:                
GAAP projected effective tax rate(2)   ~ 20%   ~ 21%   ~ 21%   ~ 16%
Income tax effect of above non-GAAP adjustments and fair value adjustments of equity securities, and discrete and related tax adjustments(2)   (~ 1%)   (~ 2%)   (~ 2%)   ~ 3%
Non-GAAP projected effective tax rate   ~ 19%   ~ 19%   ~ 19%   ~ 19%
                 
Projected diluted EPS GAAP to non-GAAP reconciliation:                
GAAP projected diluted EPS   $5.95 - $6.35   $5.65 - $6.05   $5.85 - $6.15   $6.65 - $6.85
Acquisition-related, IPR&D impairment and restructuring expenses, fair value adjustments of equity securities and discrete and related tax adjustments(2)   ~ 1.75   ~ 2.05   ~ 2.10   ~ 1.40
Non-GAAP projected diluted EPS   $7.70 - $8.10   $7.70 - $8.10   $7.95 - $8.25   $8.05 - $8.25

风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。